THERILLIA acquires TAVEC Pharmaceutical and moves it to Montreal

Therillia Development Co., a Montreal-based subsidiary of Sanderling Ventures Canada, an investor in early-stage biotech companies, has acquired TAVEC Pharmaceuticals, the leading therapeutic exosome company.. Read More →

Tavec and The Johns Hopkins University Complete Exosome Gene Therapy Worldwide Exclusive License

Tavec to further clinical development of miRNA loaded exosomes to treat cancer Exosome gene therapy platform allows highly-specific, targeted delivery of regulatory RNA to shut.. Read More →

Tavec Completes $850,000 Seed Funding

Proceeds to further pre-clinical development of exosome mediated gene therapy technology platform for cancer. NEW YORK, June 15th, 2015 – Tavec, Inc. (Tavec) announced today.. Read More →